Bicara Therapeutics (BCAX) CFO sells 1,882 shares under 10b5-1 plan

Rhea-AI Filing Summary

Bicara Therapeutics Inc. Chief Financial Officer Hyep Ivan reported an option exercise and matching share sale on January 22, 2026. Ivan exercised a stock option for 1,882 shares of common stock at $3.7898 per share, then sold 1,882 common shares at a weighted average price of $18.1522 under a pre-arranged Rule 10b5-1 trading plan adopted on February 13, 2025. Following these transactions, Ivan directly holds 145,355 shares of common stock and 65,462 stock options. The option underlying the exercised shares vests in sixteen equal quarterly installments following April 5, 2023, subject to continued service.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hyep Ivan

(Last) (First) (Middle)

BICARA THERAPEUTICS INC.

116 HUNTINGTON AVENUE, SUITE 703

(Street)

BOSTON MA 02116

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Bicara Therapeutics Inc. [ BCAX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/22/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/22/2026		M(1)		1,882	A	$3.7898	147,237	D
Common Stock	01/22/2026		S(1)		1,882	D	$18.1522(2)	145,355	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$3.7898	01/22/2026		M(1)			1,882	(3)	04/05/2033	Common Stock	1,882	$0	65,462	D

Explanation of Responses:

1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 13, 2025.

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.15 to $18.18, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

3. The shares underlying this option vest in sixteen equal quarterly installments following April 5, 2023, subject to the Reporting Person's continued service on each such vesting date.

Remarks:

	/s/ Lara Meisner, Attorney-in-Fact	01/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did BCAX CFO Hyep Ivan report on this Form 4?

Hyep Ivan, the Chief Financial Officer of Bicara Therapeutics Inc. (BCAX), reported exercising a stock option for 1,882 shares and selling 1,882 common shares on January 22, 2026.

At what prices did the BCAX CFO exercise and sell shares?

The stock option was exercised at $3.7898 per share. The 1,882 common shares were sold at a weighted average price of $18.1522, with individual sale prices ranging from $18.15 to $18.18.

Was the Bicara Therapeutics (BCAX) CFO trade under a Rule 10b5-1 plan?

Yes. The filing states the sale was executed pursuant to a Rule 10b5-1 trading plan adopted on February 13, 2025, indicating it was pre-arranged rather than opportunistic.

How many Bicara Therapeutics (BCAX) shares does the CFO own after the transactions?

After the January 22, 2026 transactions, Hyep Ivan directly owns 145,355 shares of Bicara Therapeutics common stock and 65,462 stock options.

What are the vesting terms of the BCAX stock options reported on this Form 4?

The option underlying the 1,882 exercised shares vests in sixteen equal quarterly installments following April 5, 2023, conditioned on the CFO’s continued service on each vesting date.

What is the expiration date of the Bicara Therapeutics (BCAX) stock option exercised?

The stock option exercised for 1,882 shares of Bicara Therapeutics common stock has an expiration date of April 5, 2033.